Dupilumab holds 70% biologic share in a $5B US market, but FDA black-box warnings push JAK inhibitors into second-line step-edits.

Six agents are approved for moderate-to-severe atopic dermatitis in the US, spanning two mechanism classes: four IL-4Ra biologics (dupilumab, tralokinumab, lebrikizumab, nemolizumab) and two oral JAK inhibitors (upadacitinib, abrocitinib). Dupilumab (Dupixent, Sanofi/Regeneron, approved 2017) holds approximately 70% of biologic prescriptions, backed by seven years of post-approval safety data and the broadest approved label. The addressable market is roughly 6.6 million US adults with moderate-to-severe disease.

The FDA's 2022 JAK inhibitor class black-box warning, covering malignancy, thrombosis and major cardiovascular events, has created a two-tier formulary landscape. Major commercial payers, including UHC, CVS/Aetna and Cigna, require prior biologic failure before approving JAK inhibitors, limiting upadacitinib and abrocitinib to second-line access despite superior short-term efficacy benchmarks. Pipeline agents targeting the OX40/OX40L pathway, amlitelimab and rocatinlimab, represent the next competitive wave, with Phase 3 readouts expected in 2025 to 2026.

A clean safety profile, not head-to-head efficacy, is deciding formulary position.

Five questions this report answers:

Q1 - What PA and step-edit criteria do UHC, CVS/Aetna and Cigna apply to JAK inhibitors versus biologic-naive patients?

Q2 - How does dupilumab's seven-year safety record compare to upadacitinib and abrocitinib in payer and physician decisions?

Q3 - Which pipeline agents, including amlitelimab and rocatinlimab, threaten dupilumab's 70% share by 2026?

Q4 - Why did the FDA's 2022 JAK class black-box warning create a two-tier rather than single formulary structure?

Q5 - What is Sanofi/Regeneron's lifecycle strategy for defending dupilumab ahead of biosimilar entry?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#AtopicDermatitis #US #CompetitiveIntelligence #AXLRx #PharmaMarketAccess

Live report page:  https://axlrx.ai/atopic-dermatitis/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-   hello@axlrx.ai

Web-   https://axlrx.ai/